These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 19940755)

  • 41. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006.
    Kendrick-Jones JC; Voss DM; De Zoysa JR
    Nephrology (Carlton); 2011 Feb; 16(2):243-8. PubMed ID: 21272139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
    Prasad SR; Jagirdar J
    J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS; Sheller A
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN; Gagnon AL; Darling MD; Patterson JW; Cropley TG
    JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
    J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.
    Kadiyala D; Roer DA; Perazella MA
    Am J Kidney Dis; 2009 Jan; 53(1):133-7. PubMed ID: 19022548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Nephrogenic systemic fibrosis].
    Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
    G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options.
    Schieren G; Wirtz N; Altmeyer P; Rump LC; Weiner SM; Kreuter A
    J Am Acad Dermatol; 2009 Nov; 61(5):868-74. PubMed ID: 19836645
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Focus on contrast-associated nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
    [No Abstract]   [Full Text] [Related]  

  • 53. Special issue: nephrogenic systemic fibrosis.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
    [No Abstract]   [Full Text] [Related]  

  • 54. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T; Prischl FC
    Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
    Stratta P; Canavese C; Quaglia M; Fenoglio R
    Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228
    [No Abstract]   [Full Text] [Related]  

  • 56. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
    Heverhagen JT; Krombach GA; Gizewski E
    Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M; Thuillier D; Lok C; Gras-Champel V
    Therapie; 2007; 62(2):169-72. PubMed ID: 17582319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor.
    Lu CF; Hsiao CH; Tjiu JW
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157
    [No Abstract]   [Full Text] [Related]  

  • 59. Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum.
    Naylor E; Hu S; Robinson-Bostom L
    J Am Acad Dermatol; 2008 Jan; 58(1):149-50. PubMed ID: 18158925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. UV-A1 therapy for nephrogenic systemic fibrosis.
    Tran KT; Prather HB; Cockerell CJ; Jacobe H
    Arch Dermatol; 2009 Oct; 145(10):1170-4. PubMed ID: 19841406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.